

1 **Gene expression based molecular test proves clinical validity as diagnostic aid for the**  
2 **differential diagnosis of psoriasis and eczema in formalin fixed and paraffin embedded**  
3 **tissue**

4

5 **Authors:**

6 Felix Fischer<sup>1</sup>, Sophie Roenneberg<sup>2</sup>, Larissa Graner<sup>4</sup>, Franziska Schlenker<sup>4</sup>, Roland  
7 Zengerle<sup>3,4</sup>, Fabian J. Theis<sup>1,6</sup>, Carsten B. Schmidt-Weber<sup>5</sup>, Tilo Biedermann<sup>2</sup>, Felix Lauffer<sup>2</sup>,  
8 Natalie Garzorz-Stark<sup>2</sup> and Stefanie Eyerich<sup>5,\*</sup>

9

10 **Affiliations:**

11 <sup>1</sup>Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany

12 <sup>2</sup>Department of Dermatology and Allergy, Technical University of Munich, Munich,  
13 Germany

14 <sup>3</sup>Laboratory for MEMS Applications, Department of Microsystems Engineering - IMTEK,

15 <sup>4</sup>University of Freiburg, Freiburg, Germany, Hahn-Schickard Society for Applied Research,  
16 Freiburg, Germany

17 <sup>5</sup>ZAUM – Center of Allergy and Environment, Technical University of Munich and  
18 Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich,  
19 Germany

20 <sup>6</sup>Department of Mathematics, Technical University of Munich, Garching, Germany

21 \*To whom correspondence should be addressed: stefanie.eyerich@tum.de

22

23

24

25 **Abstract**

26

27 Highly specific and efficient drugs have been developed during the last two decades to treat  
28 non-communicable chronic inflammatory skin diseases (ncISD). Due to their specificity,  
29 these drugs are asking for precise diagnostic measures to attribute the most efficient treatment  
30 to each patient. Diagnosis, however, is complicated by the complex pathogenesis of ncISD  
31 and their clinical and histological overlap. Especially, precise diagnosis of psoriasis and  
32 eczema is difficult in special cases and molecular diagnostic tools need to be developed to  
33 support gold standard diagnosis of patients. In this line, we have developed a real-time based  
34 molecular classifier to distinguish psoriasis from eczema in RNA-later fixed skin samples.  
35 However, this type of skin sample is not regularly used in routine diagnostics. Therefore, we  
36 evaluated if the combination of *NOS2* and *CCL27* expression in lesional skin can be  
37 transferred to formalin-fixed paraffin embedded (FFPE) tissue. We present a FFPE-based  
38 molecular classifier (MC) that determines the probability for psoriasis with a specificity and  
39 sensitivity of 100% and 92%, respectively, and an area under the curve (AUC) of 0.97  
40 delivering comparable results to the RNA-later based MC. The probability for psoriasis as  
41 well as the PCR result of *NOS2* expression correlated positive with disease hallmarks of  
42 psoriasis and negative with eczema hallmarks. This tool now offers broad usage in pathology  
43 laboratories and can support diagnostic decision making on a molecular level.

44

45 **Key Words**

46 Diagnostic aid; FFPE, *NOS2*; *CCL27*; inflammatory skin diseases; precision medicine

47

48

49 **Introduction**

50

51 Psoriasis and eczema are one of the most prevalent and relevant skin diseases worldwide with  
52 an incidence rate for both diseases together of at least 2,000/100,000 (Bylund, von  
53 Kobyletzki, Svalstedt, & Svensson, 2020; Thyssen, Johansen, Linneberg, & Menne, 2010;  
54 Vena et al., 2010). Although more than a dozen of specific immune-modulating therapies  
55 including biologicals and small molecules have been made available to treat patients more  
56 efficiently than ever before over the last decade (Tizek et al., 2021), the ultimate breakthrough  
57 has yet to arise due to missing accurate diagnostics tools. Diagnosis of both diseases largely  
58 depends on a subjective visual exam and histopathological examination. Due to phenotypical  
59 overlaps of both diseases up to 50 % of cases are misdiagnosed (Kolesnik, Franke, Lux,  
60 Quist, & Gollnick, 2018). To close this important diagnostic gap, a gene expression based  
61 classifier using *NOS2* and *CCL27* as marker genes has been proposed and its clinical validity  
62 has been examined and proven in various patient cohorts (Bentz et al., 2021; Brunner et al.,  
63 2018; Garzorz-Stark et al., 2016; Quaranta et al., 2014; Stoffel et al., 2018). Renert-Yuval et  
64 al. list the *NOS/CCL27* classifier as the only accepted disease classifier for psoriasis and  
65 eczema (Renert-Yuval et al., 2021). Here, we applied the molecular classifier in formalin-  
66 fixed paraffin embedded biopsy specimens of eczema and psoriasis to validate its clinical  
67 utility as diagnostic aid in pathology laboratories (n=107). We demonstrated that the FFPE-  
68 based classifier delivered the correct clinical and histopathological diagnosis on the level of  
69 RT-PCR with a test sensitivity and specificity of 92% and 100%, respectively. By opening  
70 FFPE samples to molecular diagnostics, this FFPE-based classifier can now be used in routine  
71 diagnostics and aid physician in their diagnostic decision making.

72

73

## 74 **Material and Methods**

75

### 76 *Patients and material sampling*

77 FFPE samples for this retrospective study were derived from the Biobank Biederstein and  
78 consisted of 107 patients (psoriasis, n=27; eczema, n=48, disease subtypes, n=18 and cases  
79 with contradictory diagnosis n=14)). Final diagnosis of patients was determined by at least  
80 two dermatologists taking a comprehensive view onto the clinical picture, family history,  
81 laboratory parameters and histological assessment. Characteristics of all patients are shown in  
82 Table 1. Patients treated with immune-efficient medication prior to material sampling were  
83 excluded from the study. The study was approved by the local ethical committee (project  
84 number 2773/10 and 515/17). Generated data and codes can be provided upon request.

85

### 86 *Characteristics of FFPE tissue and isolation of total RNA*

87 Skin biopsies (Ø3-6mm) from patients with a potential diagnosis of psoriasis or eczema were  
88 taken under local anesthesia by a dermatologist and immediately fixed in neutral buffered  
89 formalin for 8-48 hours at room temperature or 4°C. Fixed biopsies were paraffin embedded  
90 according to standard procedures (one biopsy per paraffin cassette). Unstained FFPE skin  
91 biopsies (<10 years of age) were used to isolate mRNA. Here, tissue sections with a thickness  
92 of 10 µm were generated from each FFPE skin sample. The first sections containing both  
93 epidermis and dermis were trimmed (at least 30µM) and discarded to avoid usage of degraded  
94 material. mRNA was extracted from in total three FFPE sections using a magnetic bead-based

95 purification method according to the manufacturer's protocol (InnuPREP MP Basic FFPE  
96 RNA Kit, IST Innuscreen, Germany). The mRNA eluates were analyzed immediately after  
97 the extraction by real-time PCR using specific primer and hydrolysis probes.

98

#### 99 *Primer design and Real-time PCR*

100 For specific amplification of the genes of interests *NOS2* and *CCL27* as well as of the  
101 reference genes, *TBP* and *SDHAF2*, primers and hydrolysis probes were designed using the  
102 primer design tool PrimerBLAST from NCBI ([https://www.ncbi.nlm.nih.gov/tools/primer-](https://www.ncbi.nlm.nih.gov/tools/primer-blast/)  
103 [blast/](https://www.ncbi.nlm.nih.gov/tools/primer-blast/)). Oligonucleotides were synthesized by biomers (Germany). Probes were labeled with  
104 an Atto 647N fluorophore at the 5'-end and quenched with a BHQ2 quencher at the 3'-end.

105 Primer and probe sequences were as follows (forward, reverse and probe): 5'-  
106 TTCCTGGTTTGACTGTCCTTACC-3', 5'- T7TTCCTGTTGGGGCTTGC-3' and 5'-  
107 CGGGGAGGCAGTGCAGCCAGC-3' for *NOS2*; 5'- ACCCTACAGCAGCATTCTTAC-3',  
108 5'- AGCTTGTCTGAGAGTGGCTTTC-3' and 5'-  
109 ACCCAGCACTGCCTGCTGTACTCAGCTC-3' for *CCL27*; 5'-  
110 ATGGATCAGAACAACAGCCTGC-3', 5'- CATTGGACTAAAGATAGGGATTCCG-3'  
111 and 5'-TCAGGGCTTGGCCTCCCCTCAGGGTGCC-3' for *TBP*; 5'-  
112 CGGTGTCTACAGTGTCTCGAC-3', 5'- GATGTCACACTGAGCAAAGGAG-3' and 5'-  
113 CGCTGATGCTTGCTCTGTCAAGGCACAGCC-3' for *SDHAF2*.

114 Real-time PCR reactions were carried out in 96-well plates using a Thermo Fisher Scientific  
115 one-step RT-PCR master mix. Thermocycling and fluorescence detection were performed in a  
116 qTower<sup>3</sup> (Analytik Jena, Germany) and amplification results were analyzed using the  
117 qPCRsoft 4.1 software (Analytik Jena).

118

119 *FFPE-based molecular classifier (MC) built-up*

120 The molecular classifier was built using L2 regularized logistic regression. The molecular  
121 classifier predicts the disease state (probability for psoriasis) directly from the normalized CT  
122 values of *NOS2* and *CCL27* normalized to the reference genes *SDHAF2* and *TBP*. For  
123 classification the psoriasis and eczema subtypes are aggregated to their respective high level  
124 labels (eczema or psoriasis). The model was calculated using LinearRegression  
125 implementation from scikit-learn with an L2 regularization strength of 100. In addition, the  
126 uncertainty of the model is estimated based on the predicted probability (cases with a  
127 predicted probability between 45% and 55% are predicted as undetermined). The model was  
128 trained on 77 patients with a clear diagnosis of psoriasis and eczema (atopic dermatitis (AD)  
129 and nummular eczema (NE)) and achieved an AUC of 0.97 +/- 0.06 on the training data.  
130 Furthermore, the model achieved a sensitivity = 91% and a specificity = 91% on the  
131 evaluation set which includes the training data plus 18 additional patients with prediagnosed  
132 subtypes of psoriasis and eczema.

133

134 *Correlation of FFPE-based MC probability and PCR results with clinical attributes*

135 Pearson correlation coefficients were calculated to determine the correlation between the  
136 FFPE-based MC determined probabilities for psoriasis, the negative delta CT PCR results of  
137 *CCL27* and *NOS2* as well as histological parameters, morphology of the lesion, comorbidities,  
138 laboratory parameters and family history.

139 **Results**

140 **The FFPE-based molecular classifier (MC) precisely separates eczema from psoriasis**  
141 **and efficiently identifies subtypes of both diseases**

142 To evaluate the potential of FFPE samples for molecular diagnostics, 76 FFPE samples of  
143 lesional psoriasis (n=27) and eczema (atopic dermatitis n=28; nummular eczema n=21) were  
144 analyzed by probe-based real-time PCR for the expression of *NOS2* and *CCL27*. To calculate  
145 a FFPE-based molecular classifier (MC) for differentiation of psoriasis and eczema, a logistic  
146 regression model was fitted with a 5-times cross validation. This classifier was designed to  
147 predict the probability of psoriasis with a cut-off value of 55% (The range between 45% and  
148 55% would no probability (undetermined). Test specificity for psoriasis was 100% with a  
149 sensitivity of 92% and an area under the ROC curve (AUC) of 0.97 +/- 0.06 (Fig. 1A). Two  
150 psoriasis patients were mis-classified, and two further psoriasis patients reached a probability  
151 between 45-55% and thereby could not be evaluated (Fig. 1B). In a next step, we used the  
152 FFPE-based MC to classify subtypes of psoriasis (psoriasis guttata n=5; psoriasis  
153 palmoplantaris n=1; generalized pustular psoriasis n=2; and psoriasis pustulosa  
154 palmoplantaris n=3) and eczema (dishidrotic eczema n=4; hyperkeratotic rhagadiforme  
155 eczema n=3) (Fig. 1B). Whereas all cases of psoriasis guttata, psoriasis palmoplantaris and  
156 psoriasis pustulosa pampoplantaris were diagnosed correctly by the FFPE-based MC, cases of  
157 dishidrotic and hyperkeratotic-rhagadiform eczema as well as generalized pustular psoriasis  
158 tended to be misdiagnosed.

159

160 ***FFPE classifier results correlate with clinical attributes of psoriasis and eczema***

161 To understand if the determined probability for psoriasis also correlates with clinical  
162 attributes associated with psoriasis or eczema, Person correlation coefficients were

163 determined (Fig. 2). The probability of psoriasis highly and positively correlated with the  
164 histological attributes 'dilated dermal capillaries' ( $r=0.61$ ), 'acanthosis' ( $r=0.51$ ), 'neutrophils'  
165 ( $r=0.39$ ) and 'parakeratosis' ( $r=0.33$ ) (Fig. 2) – all hallmarks for the pathogenesis of psoriasis.  
166 This positive correlation was followed by a positive correlation of negative CT values of  
167 *NOS2* ( $r=0.43$ ;  $r=0.33$ ;  $r=0.23$ ;  $r=0.25$ , respectively) and a negative correlation with negative  
168 delta CT values for *CCL27* ( $r=-0.54$ ;  $r=-0.5$ ;  $r=-0.48$ ;  $r=-0.22$ , respectively). In line, the  
169 probability of psoriasis and the negative delta CT for *NOS2* correlated positive with a  
170 psoriasis type morphology ( $r=0.77$  and  $r=0.56$ ) and arthritis ( $r=0.34$  and  $r=0.35$ ), whereas a  
171 negative correlation was determined for an eczema type morphology ( $r=-0.77$  and  $r=-0.56$ )  
172 and rhinoconjunctivitis allergica (RCA) ( $r=-0.47$  and  $r=-0.28$ ) (Fig. 2). The probability of  
173 psoriasis also correlated positive with the therapeutic efficiency of IL12/IL-23 ( $r=0.99$ ) and  
174 TNF- $\alpha$  inhibition ( $r=0.56$ ), however negative with the response to Fumarate ( $r=-0.34$ ) of IL-17  
175 inhibition ( $r=-0.74$ ). No correlations of the laboratory parameters 'Stap.aureus' and specific  
176 'IgE' as well as the family history of for psoriasis and eczema were identified.

177

### 178 **The FFPE-based MC supports diagnostic decision making in patients with inconsistent** 179 **diagnosis**

180 To further evaluate the potential of the FFPE-based MC to support diagnostic decision  
181 making, 14 patient samples with discrepant clinical and histological diagnosis were analyzed.  
182 Within this cohort, 9 patients were assigned a probability for psoriasis and 5 patients were  
183 classified as eczema (Fig. 3A). Patient 43, a close to 80 year old woman, developed shortly  
184 after a respiratory infection itchy, pustular reddening overall the whole body. Bacterial or  
185 viral infections were not detected. Extensive lesional skin at the thigh and knee were  
186 surgically excised. Histologically, the lesions presented with infiltration of neutrophils and  
187 isolated eosinophils, signs of spongiosis and in part parakeratosis. The patient was diagnosed



188 with psoriasis pustulosa, however, acute generalized exanthematic pustulosis (AGEP) could  
189 not be ruled out. In fact, psoriasis pustulosa and AGEP can hardly be distinguished by  
190 classical histological examination. Our FFPE-based MC assigned this patient a probability of  
191 psoriasis of 74.49%. After initiation of Ixekizumab, the skin status of this patient improved  
192 supporting the MC-based classification (Fig. 3B).

193 Patient 59, a mid-sixty male, presented in the clinic with reddish, hyperkeratotic, scaly and  
194 itchy skin lesions at both palmae accompanied by erythematous, heavily infiltrated plaques at  
195 the back, the capillitium and retroauricular. Histopathological examination showed  
196 psoriasiform acanthosis, hyperparakeratosis, a lymphocytic infiltrate and isolated plasma cells  
197 leading to the diagnosis of psoriasiform perivascular dermatitis, while clinically diagnostics  
198 was in favor for psoriasis. The FFPE-based MC assigned a probability for psoriasis of  
199 99.53%. Skin lesions at the palms and body cleared after 6 months of methothrexate therapy  
200 (Fig. 3B).

201 Patient 62, a male at the end of his sixties, presented at the clinic with confluent,  
202 erythematous, crude-lamellar, scaly plaques at both palmae. Histologically, extended  
203 hyperparakeratosis, serum crusts, psoriasiforme epidermis hyperplasia combined with  
204 spongiosis and a linear lymphocytic infiltrate in absence of neutrophils and eosinophils was  
205 described leading to the diagnosis of hyperkeratotic, in part dyshidrotic hand eczema. The  
206 FFPE-based MC assigned this patient a probability for psoriasis of 8.25% and thereby a high  
207 likelihood of an underlying eczematous disease. Treatment with a topical corticosteroids and  
208 altitretinoin improved the skin lesions supporting the MC-based classification (Fig. 3B).

209 Patient 75, a woman at beginning of her sixties, has been suffering for years under recurrent  
210 itchy, sharply demarcated erythematous plaques, with in part lamellar scales and excoriations  
211 as clinically seen in both psoriasis and eczema variants. Histologically, a psoriasiform  
212 hyperplasia of the epidermis combined with hyperparakeratosis, hypogranulosis, elongated  
213 rete-ridges, papillomatosis and focal spongiosis in upper epidermis layers was found. A

214 perivascular dense lymphocytic infiltrate with absence of neutrophils and eosinophils was  
215 identified. The patient was diagnosed with a nummular eczema. This is supported also by the  
216 FFPE-based MC that assigned a probability of 18.29% to this patient (Fig. 3B) and skin  
217 lesions improved with topical corticosteroids and UVB phototherapy.

218

219

220

## 221 **Discussion**

222 The development of highly specific biologic drugs has revolutionized treatment options for  
223 various diseases during the past two decades (Noda, Krueger, & Guttman-Yassky, 2015).  
224 However, due to their specificity, these drugs are most efficient in only a small group of  
225 diseases and patients calling for efficient diagnosis and subsequent assignment of each patient  
226 to the most appropriate drug. Whereas molecular diagnostics have been already developed  
227 and used for cancer diagnosis followed by decision making on treatment regimens, they are  
228 not well established in the field of chronic inflammatory skin diseases, yet (Grazia, Penna,  
229 Perotti, Anichini, & Tassi, 2014; Levine & Fisher, 2014; Usher-Smith, Emery, Kassianos, &  
230 Walter, 2014). In previous work, we have developed a disease classifier to dissect psoriasis  
231 from eczema based on the expression levels of *NOS2* and *CCL27* (Quaranta et al., 2014;  
232 Garzorz-Stark et al., 2016). This classifier has been validated by several groups and found its  
233 acceptance in the field (Bentz et al., 2021; Brunner et al., 2018; Stoffel et al., 2018). However,  
234 it was established on RNA-later fixed skin that is regularly used in research, but not in clinics,  
235 private practices and pathology laboratories. Within these institutions, skin samples usually  
236 are formalin fixed and paraffin embedded (FFPE). This way of fixation allows long-term  
237 storage of samples and optimal assessment of histological hallmarks, however, by cross-  
238 linking of proteins with RNA and RNA degradation due to the fixation procedure, RNA  
239 isolation from FFPE samples can be challenging. Here, optimized protocols have been  
240 developed to minimize side effects of the fixation method and now allow to use this sample  
241 type for efficient diagnostics. Within this work, we have transferred the RNA-later molecular  
242 classifier to FFPE samples and were able to retrieve comparable results. Whereas the RNA-  
243 later based MC dissected psoriasis from eczema with a specificity and sensitivity for psoriasis  
244 of 100% and 97.7%, respectively and an AUC of 0.99, the FFPE-based classifier determined  
245 probabilities for psoriasis with a specificity and sensitivity of 100% and 92%, respectively,  
246 and an AUC of 0.97 (Garzorz-Stark et al., 2016). Whereas only two classical psoriasis

247 samples were not classified correctly by the FFPE-based MC, all atopic dermatitis and  
248 nummular eczema cases were diagnosed precisely. The FFPE-based MC was also able to  
249 predict the diagnosis of psoriasis subtypes, however, delivered conflicting results for  
250 dyshidrotic and hyperkeratotic-rhagadiform eczema. Unfortunately, the cohort of these  
251 subtypes was very small (4 and 3 cases, respectively) and data on treatment regimens and  
252 therapeutic efficiency were not available. As these patients are difficult to diagnose by gold  
253 standard diagnostics, further studies need to be undertaken to prove the efficiency of  
254 molecular classification in this eczema subtype. In addition, and in line with previous  
255 findings, the FFPE-based classifier probability highly correlated with disease hallmarks of  
256 psoriasis, but not hallmarks of eczema (Garzorz-Stark et al., 2016). Therefore, the reliability  
257 of the two markers, *NOS2* and *CCL27*, has been shown now also in a FFPE tissue arguing for  
258 implementation of this molecular diagnostic aid in clinical routine diagnostics and pathology  
259 laboratories. Here, however, further efforts have to be undertaken to simplify and speed up  
260 the labor- and cost-intensive purification of RNA from FFPE tissue. In addition, fully  
261 automated systems need to be developed to be integrated into the processes in routine  
262 diagnostic laboratories.

263

264

265

266

## 267 **Acknowledgments**

268 The authors thank Kerstin Weber for excellent technical support and the Biobank Biederstein  
269 for patient samples. This work was supported by the Medical Valley Award.

270

271 **References**

- 272 Bentz, P., Eyerich, K., Weber, K., Kluge, L., Ofenloch, R., & Weisshaar, E. (2021). [Cohort study for  
273 long-term follow-up of patients in whom the so-called "molecular classifier" is used to distinguish  
274 eczema from psoriasis: Background and implementation]. *Hautarzt*, 72(4), 354-357.  
275 doi:10.1007/s00105-021-04774-9
- 276 Brunner, P. M., Pavel, A. B., Khattri, S., Leonard, A., Malik, K., Rose, S., . . . Guttman-Yassky, E.  
277 (2018). Baseline IL22 expression in atopic dermatitis patients stratifies tissue responses to  
278 fezakinumab. *J Allergy Clin Immunol*. doi:10.1016/j.jaci.2018.07.028
- 279 Bylund, S., von Kobyletzki, L. B., Svalstedt, M., & Svensson, A. (2020). Prevalence and Incidence of  
280 Atopic Dermatitis: A Systematic Review. *Acta Derm Venereol*, 100(12), adv00160.  
281 doi:10.2340/00015555-3510
- 282 Garzorz-Stark, N., Krause, L., Lauffer, F., Atenhan, A., Thomas, J., Stark, S. P., . . . Eyerich, K.  
283 (2016). A novel molecular disease classifier for psoriasis and eczema. *Exp Dermatol*, 25(10), 767-774.  
284 doi:10.1111/exd.13077
- 285 Grazia, G., Penna, I., Perotti, V., Anichini, A., & Tassi, E. (2014). Towards combinatorial targeted  
286 therapy in melanoma: from pre-clinical evidence to clinical application (review). *Int J Oncol*, 45(3),  
287 929-949. doi:10.3892/ijo.2014.2491
- 288 Kolesnik, M., Franke, I., Lux, A., Quist, S. R., & Gollnick, H. P. (2018). Eczema in Psoriatico: An  
289 Important Differential Diagnosis Between Chronic Allergic Contact Dermatitis and Psoriasis in  
290 Palmoplantar Localization. *Acta Derm Venereol*, 98(1), 50-58. doi:10.2340/00015555-2779
- 291 Levine, D., & Fisher, D. E. (2014). Current status of diagnostic and prognostic markers in melanoma.  
292 *Methods Mol Biol*, 1102, 177-197. doi:10.1007/978-1-62703-727-3\_11
- 293 Noda, S., Krueger, J. G., & Guttman-Yassky, E. (2015). The translational revolution and use of  
294 biologics in patients with inflammatory skin diseases. *J Allergy Clin Immunol*, 135(2), 324-336.  
295 doi:10.1016/j.jaci.2014.11.015

- 296 Quaranta, M., Knapp, B., Garzorz, N., Mattii, M., Pullabhatla, V., Pennino, D., . . . Eyerich, K. (2014).  
297 Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and  
298 eczema. *Sci Transl Med*, 6(244), 244ra290. doi:10.1126/scitranslmed.3008946
- 299 Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-  
300 Yassky, E. (2021). Biomarkers in atopic dermatitis-a review on behalf of the International Eczema  
301 Council. *J Allergy Clin Immunol*, 147(4), 1174-1190 e1171. doi:10.1016/j.jaci.2021.01.013
- 302 Stoffel, E., Maier, H., Riedl, E., Bruggen, M. C., Reiningger, B., Schaschinger, M., . . . Brunner, P. M.  
303 (2018). Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1  
304 activation with some distinct immunological characteristics. *Br J Dermatol*, 178(5), 1151-1162.  
305 doi:10.1111/bjd.16126
- 306 Thyssen, J. P., Johansen, J. D., Linneberg, A., & Menne, T. (2010). The epidemiology of hand eczema  
307 in the general population--prevalence and main findings. *Contact Dermatitis*, 62(2), 75-87.  
308 doi:10.1111/j.1600-0536.2009.01669.x
- 309 Tizek, L., Schuster, B., Gebhardt, C., Reich, K., von Kiedrowski, R., Biedermann, T., . . . Garzorz-  
310 Stark, N. (2021). Molecular diagnostics in dermatology: An online survey to study usage, obstacles  
311 and requirements in Germany. *J Dtsch Dermatol Ges*. doi:10.1111/ddg.14659
- 312 Usher-Smith, J. A., Emery, J., Kassianos, A. P., & Walter, F. M. (2014). Risk prediction models for  
313 melanoma: a systematic review. *Cancer Epidemiol Biomarkers Prev*, 23(8), 1450-1463.  
314 doi:10.1158/1055-9965.EPI-14-0295
- 315 Vena, G. A., Altomare, G., Ayala, F., Berardesca, E., Calzavara-Pinton, P., Chimenti, S., . . . Cricelli,  
316 C. (2010). Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational  
317 study from a national primary care database. *Eur J Dermatol*, 20(5), 593-598.  
318 doi:10.1684/ejd.2010.1017
- 319
- 320

321

322 **Tables**


	n	age		n	age
<i>psoriasis (pso) (n=27)</i>			<i>atopic dermatitis (n=28)</i>		
m	20	49.7±12.56	m	13	47.69±25.82
w	7	65.86±10.12	w	15	55.67±29.08
<i>psoriasis guttata (PG) (n=5)</i>			<i>nummular eczema (n=21)</i>		
m	2	36.5±5.5	m	10	62.6±15.32
w	3	40.23±3.86	w	11	72±14.25
<i>generalized pustular psoriasis (GPP) (n=2)</i>			<i>dyshidrotic eczema (DHE) (n=4)</i>		
m	1	55-60	m	1	70-75
w	1	25-30	w	3	55.67±19.29
<i>psoriasis palmoplantaris (PP) (n=1)</i>			<i>hyperkeratotic-rhagadiform eczema (HRE) (n=3)</i>		
w	1	40-45	m	1	60-65
<i>psoriasis pustulosa palmoplantaris (PPP) (n=3)</i>			w	2	70±21.21
m	2	42±9.9	<i>unclear cases (n=14)</i>		
w	1	45-50	m	8	56.86±13.36
			w	6	66±9.7

323

324 **Table 1: Patient characteristics**

325

326 **Figures and figure legends**



327

328 **Figure 1:** The FFPE-based Molecular classifier (MC) dissects clinically clear cases of  
329 psoriasis and eczema and is also efficient in subtypes of both diseases.

330 A) The molecular classifier (MC) was trained on clear cases of eczema (atopic dermatitis (AD  
331 n=28), nummular eczema (NE, n=21) and psoriasis (Pso, n=27) using a logistic regression  
332 model with a 5-fold cross validation delivering the probability of psoriasis. CT values of  
333 *NOS2* and *CCL27* were normalized to the reference genes *SDHAF2* and *TBP*. The graph  
334 indicates the dissection of eczema and psoriasis samples exemplarily for normalization B)  
335 FFPE-based MC determined probabilities for psoriasis in clear cases of atopic dermatitis  
336 (AD), nummular eczema (NE) and psoriasis (Pso). The grey are between 45%-55% indicates  
337 undetermined probabilities C) The FFPE-based MC was used to predict the probability for  
338 psoriasis in subtypes of eczema and psoriasis (dyshidrotic eczema, DHE n=; hyperkeratotic-  
339 rhagadiform eczema, HRE n=; psoriasis guttata, PG n=5; psoriasis palmoplantaris, PP n=1);  
340 generalized pustular psoriasis, GPP n=2; and psoriasis pustulosa palmplantaris, PPP n=2). A  
341 probability between 45% and 55% was defined as not evaluable.


342

343

344




Fig. 2



345

346 **Figure 2:** The FFPE-based MC determined probability for psoriasis correlates with disease  
 347 hallmarks.

348 The probability for psoriasis as well as the negative delta CT values for CCL27 and NOS2  
 349 were correlated with clinical attributes by Pearson correlation.



350

351 **Figure 3:** The FFPE-based MC is able to support diagnosis of unclear cases.

352 A) The FFPE-based MC was applied on clinically and histologically challenging cases of  
353 patients with a suspected diagnosis of psoriasis or eczema and subtypes of both diseases  
354 (n=14). Given patient numbers represent numerical numbering and not biobank IDs. B)  
355 Clinical pictures and histological H&E stainings of selected patients that were assigned a  
356 probability of psoriasis by the FFPE-based MC.

357